Clinical Trial Update: A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating BL-B01D1 in combination with pembrolizumab, with or without bevacizumab, for recurrent or metastatic cervical cancer and endometrial ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer

Drugs mentioned

• BL-B01D1
• Bevacizumab (bevacizumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Cervical Cancer, Endometrial Cancer | Phase 2 | Status: RECRUITING